Clinical Trials Logo

Clinical Trial Summary

Study of Chidamide as a Single-agent Treatment for Patients With Recurrent and Metastatic Epstein-Barr virus (EBV)-associated Solid Tumors

Clinical Trial Description

Chidamideļ¼Œa novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide as a single-agent treatment in patients with recurrent and metastatic Epstein-Barr virus (EBV)-associated solid tumors. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03494634
Study type Interventional
Source Sun Yat-sen University
Contact Li Zhang, MD
Phone 86-20-87343458
Status Not yet recruiting
Phase Phase 2
Start date April 15, 2018
Completion date September 30, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03611231 - Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma Phase 2
Recruiting NCT03617432 - Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients Phase 2